These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25591817)

  • 1. Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer.
    Polders DL; Steggerda M; van Herk M; Nichol K; Witteveen T; Moonen L; Nijkamp J; van der Heide UA
    Acta Oncol; 2015 Jun; 54(6):839-46. PubMed ID: 25591817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy.
    Crook J; Patil N; Ma C; McLean M; Borg J
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1079-84. PubMed ID: 19879700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment margins for prostate brachytherapy.
    Han B; Wallner K; Aggarwal S; Armstrong J; Sutlief S
    Semin Urol Oncol; 2000 May; 18(2):137-41. PubMed ID: 10875455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
    Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
    Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage.
    Brun T; Bachaud JM; Graff-Cailleaud P; Malavaud B; Portalez D; Popotte C; Aziza R; Lusque A; Filleron T; Ken S
    Brachytherapy; 2018; 17(3):544-555. PubMed ID: 29525514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
    Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
    Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetry modeling for focal high-dose-rate prostate brachytherapy.
    Mason J; Al-Qaisieh B; Bownes P; Thwaites D; Henry A
    Brachytherapy; 2014; 13(6):611-7. PubMed ID: 25085456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
    Pickett B; Pouliot J
    Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved tumour control probability with MRI-based prostate brachytherapy treatment planning.
    Dinkla AM; Pieters BR; Koedooder K; van Wieringen N; van der Laarse R; van der Grient JN; Rasch CR; Koning CC; Bel A
    Acta Oncol; 2013 Apr; 52(3):658-65. PubMed ID: 23282111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
    Al-Qaisieh B; Witteveen T; Carey B; Henry A; Bottomley D; Smith J; Franks K; Bownes P
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):626-30. PubMed ID: 19540077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dependence of prostate postimplant dosimetric quality on CT volume determination.
    Merrick GS; Butler WM; Dorsey AT; Lief JH
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1111-7. PubMed ID: 10421545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal prostate brachytherapy with (103)Pd seeds.
    Butler WM; Merrick GS
    Phys Med; 2016 Mar; 32(3):459-64. PubMed ID: 27053451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brachytherapy in patients with small prostate glands.
    Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
    Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate prostate brachytherapy consistently results in high quality dosimetry.
    White EC; Kamrava MR; Demarco J; Park SJ; Wang PC; Kayode O; Steinberg ML; Demanes DJ
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):543-8. PubMed ID: 22652111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
    Todor DA; Barani IJ; Lin PS; Anscher MS
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
    Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy.
    Roeloffzen EM; Battermann JJ; van Deursen MJ; Monninkhof EM; Visscher MI; Moerland MA; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1072-9. PubMed ID: 20615621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of prostate implants based on postimplant treatment margin assessment.
    Mueller A; Wallner K; Merrick G; Courveau J; Sutlief S; Butler W; Gong L; Cho P
    Med Phys; 2002 Dec; 29(12):2782-7. PubMed ID: 12512711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse automated treatment planning with and without individual optimization in interstitial permanent prostate brachytherapy with high- and low-activity 125I.
    Pinkawa M; Maurer U; Mulhern A; Gagel B; Block T; Borchers H; Grieger J; Henkel T; Eble M
    Strahlenther Onkol; 2003 Jun; 179(6):417-22. PubMed ID: 12789469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.